Antagonism of Sorafenib and Regorafenib actions by platelet factors in hepatocellular carcinoma cell lines

BACKGROUND: Platelets are frequently altered in hepatocellular carcinoma (HCC) patients. Platelet lysates (hPL) can enhance HCC cell growth and decrease apoptosis. The aims were to evaluate whether hPL can modulate the actions of Sorafenib or Regorafenib, two clinical HCC multikinase antagonists. ME...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: D’Alessandro, Rosalba, Refolo, Maria G, Lippolis, Catia, Giannuzzi, Grazia, Carella, Nicola, Messa, Caterina, Cavallini, Aldo, Carr, Brian I
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2014
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4038078/
https://ncbi.nlm.nih.gov/pubmed/24885890
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-14-351
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars